Eevia Health ("Eevia" or "The Company") received a sales order from a US customer for the elderberry extract Feno-Sambucus™ 7 Organic for a value of just over USD 200k or EUR 187k.
The order for Feno-Sambucus™ 7 Organic is for a value of approx. EUR 187k (USD 201k) from Select Ingredients (United States) and will be delivered over 3 deliveries during 2023, the first one in February.
FENO-SAMBUCUS™ 7 Organic is a certified organic elderberry extract standardized at 7% anthocyanins. Eevia uses a special purification technology that purifies the product based on chemical class. This process leaves other important bioactive compounds present in the extract, such as oligomeric proanthocyanidins (OPCs). Besides the organic certification, this feature differentiates Eevia's elderberry extract from other elderberry extracts in the market made using membrane filtration technology. The latter processing approach purifies the extract based on molecular size and reduces the presence of large bioactive compounds such as the OPCs.
The end customer is a large organic food and beverage brand that uses the elderberry ingredient from Eevia in nutraceutical and food formulations for sales primarily in the North American market. The customer has a leading market share nationally in the US in certain beverage and food categories based on an uncompromising brand commitment to natural, organic products of high quality.
Select Ingredients is one of Eevia's two distributors in the US. Select is known for its specialization in organic certified products and high-quality natural plant extracts. Select is headquartered in San Diego, California, and has a strong presence in the Golden State and other large states in the US.
CEO Stein Ulve comments: "We are pleased to see our superior organic European Elderberry extracts succeed in competition with other less bioactive extracts in the North American market."
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com
Telephone: +358 400 22 5967
This information is such that Eevia Health Plc is required to make it public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on January 18th, 2023, at 12:20 CET.
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.